STAT+: Oura goes public, reported $1.2B earnings in its last fiscal year

STAT PlusNewsletterHealth Tech Newsletter Oura goes public, reported $1.2B earnings in its last fiscal year In health tech news today, Oura reports a profit, the FDA loses another key digital health leader, and more Manage alerts for this article Email this article Share this article By Mario AguilarSept. 8, 2026 Health Tech Correspondent Mario Aguilar[email protected]Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer wearables. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter.

You can reach Mario on Signal at mariojoze.13. Good morning health tech readers! I hope you had a wonderful long weekend.Advertisement Reach me: [email protected] STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In health tech, Health Tech Newsletter Submit a correction requestReprints Mario Aguilar Health Tech Correspondent Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer wearables.

He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can reach Mario on Signal at mariojoze.13. Newsletter Tech is transforming health care and life sciences.

Our original reporting is here to keep you ahead of the curve. Recommended The Readout September 8, 2026 STAT Plus: FDA approves AstraZeneca breast cancer drug Biotech September 8, 2026 STAT Plus: Inhibrx claims first win for long-sought immunotherapy target Advertisement Biotech September 8, 2026 STAT Plus: Roivant lung disease drug hits mid-stage study goals Pharma September 7, 2026 STAT Plus: Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation Pharma September 4, 2026 STAT Plus: Novartis’ experimental cardiovascular drug fails a pivotal study Subscriber Picks